French pharma major Sanofi and US partner Regeneron Pharmaceuticals yesterday presented positive results from the EVEREST ...

Upstream Bio (UPB) shares saw an increase in after-hours trading on Friday following the company's presentation of ...

Pharmacology modeling data presented at the European Academy of Allergy & Clinical Immunology (EAACI) Congress describe ...

Type 2 CRSwNP is linked to worse health-related quality of life, with higher rates of smell loss and rhinorrhea emerging as ...

A new Canadian real-world study, ACTIONS (chAracterizing oral Corticosteroid use in patients with chronic rhInOsinusitis with ...

In patients with chronic rhinosinusitis with nasal polyps, factors including baseline antibiotic use and asthma impacted the ...

Purpose This review aims to explore the pathophysiological mechanisms and emerging therapies for type 2 chronic rhinosinusitis with nasal polyps (CRSwNP), driven primarily by type 2 ...

Paris: Sanofi has announced that the AERIFY-1 phase 3 study evaluating itepekimab in former smokers with inadequately controlled chronic obstructive pulmonary disease (COPD) met the ...

chronic obstructive pulmonary disease (COPD), prurigo nodularis (PN), chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic esophagitis (EoE), bullous pemphigoid (BP), and chronic ...

Itepekimab is currently being evaluated in other studies, including chronic rhinosinusitis with nasal polyps (CRSwNP), chronic rhinosinusitis without nasal polyps (CRSsNP), and bronchiectasis. "COPD ...

CRSwNP recurrence after surgery is linked to high eosinophils, GERD, diabetes, and asthma. A new model accurately predicts recurrence risk. “Chronic rhinosinusitis with nasal polyps (CRSwNP) is a ...